Nilesh Patil, MD
Urology · Cincinnati, OHNPI 1497904205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,314 of the $1,797 with a category attached, or 73.1%. 20 manufacturers reported payments, led by Astellas Pharma US Inc at 26.8% of the total. Reporting peaked in 2019 at $531 and has fallen 67.9% since, to $170 in 2025. That places this record below the midpoint for urology clinicians in OH, where the typical reported total is $2,547.
Across 60 payments — averaging $29.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$482
- Janssen Scientific Affairs, LLC$227
- C. R. Bard, Inc. & Subsidiaries$214
- Johnson & Johnson$149
- Axonics, Inc.$117
- AstraZeneca$113
- plus $495 from 14 others
Across 10 payments — averaging $7869.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Angiodynamics, Inc.$79K
What the payments were for
- Food & beverage$1,31473%
- Education$48327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 10 | $482 |
| Janssen Scientific Affairs, LLC | 2 | $227 |
| C. R. Bard, Inc. & Subsidiaries | 15 | $214 |
| Johnson & Johnson(2 entities) | 8 | $149 |
| Axonics, Inc. | 1 | $117 |
| AstraZeneca | 1 | $113 |
| AbbVie | 5 | $89 |
| Intuitive Surgical | 1 | $82 |
| Pfizer | 4 | $55 |
| Urogen Pharma, Inc. | 1 | $40 |
| Myovant Sciences Inc. | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Rochester Medical Corporation | 2 | $24 |
| Coloplast | 1 | $22 |
| Olympus America Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,797 in reported general payments places this provider in the 40th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 45 | $631,291 |
| OrgovyxRelugolix | 22 | $59,761 |
| MyrbetriqMirabegron | 88 | $54,788 |
| Abiraterone Acetate | 35 | $29,608 |
| Tamsulosin Hcl | 503 | $5,498 |
| Finasteride | 156 | $1,789 |
| Silodosin | 13 | $1,021 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 20 | $906 |
| Oxybutynin Chloride | 28 | $765 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $588 |
| Prednisone | 18 | $127 |
| Sildenafil Citrate | 17 | $106 |
| Ciprofloxacin Hcl | 20 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $482 | $686,078133 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $27 | $59,76122 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $227 | $29,60835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 485 urology providers in Ohio.
Other urology in Cincinnati
- Abhinav SidanaCincinnati$174K
- Paurush BabbarCincinnati$140K
- Marc PliskinCincinnati$108K
- Stephen BennettCincinnati$38K
- Michael RousseauCincinnati$26K
- Kamal PoharCincinnati$20K
- Ryan FlynnCincinnati$16K
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.